References
- Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumors of female reproductive organs. Lyon, France: International Agency for Reserch on Cancer; 2014.
- Inoue M, Sakaguchi J, Sasagawa T, Tango M. The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer. 2006;16(3):1007–13. doi:10.1111/j.1525-1438.2006.00460.x. PMID: 16803477.
- Manini I, Montomoli E. Epidemiology and prevention of human Papillomavirus. Annali di igiene: medicina preventiva e di comunita. 2018;30(4Supple 1):28–32. doi:10.7416/ai.2018.2231. PMID: 30062377.
- Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007;196(10):1438–46. doi:10.1086/522864. FUTURE II Study Group. PMID: 18008221.
- Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14. doi:10.1016/S0140-6736(09)61248-4. PMID: 19586656.
- Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, Whiteman DC. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458. doi:10.1136/bmj.g1458. PMID: 24594809.
- Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia–nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014;106(3):djt460. doi:10.1093/jnci/djt460.
- Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Cruickshank M, Palmer TJ, Nicoll S. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111(9):1824–30. doi:10.1093/jnci/djt460. PMID: 24552678.
- Petry KU, Bollaerts K, Bonanni P, Stanley M, Drury R, Joura E, Kjaer SK, Meijer CJLM, Riethmuller D, Soubeyrand B, et al. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine. Hum Vaccin Immunother. 2018;14(7):1800–06. doi:10.1080/21645515.2018.1450125. PMID: 29553886.
- Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: results of the Nagoya study. Papillomavirus Res (Amsterdam, Netherlands). 2018;5:96–103. doi:10.1016/j.pvr.2018.02.002. PMID: 29481964.
- Yamaguchi M, Sekine M, Kudo R, Adachi S, Ueda Y, Miyagi E, Hara M, Hanley SJB, Enomoto T. Differential misclassification between self-reported status and official HPV vaccination records in Japan: implications for evaluating vaccine safety and effectiveness. Papillomavirus Res (Amsterdam, Netherlands). 2018;6:6–10. doi:10.1016/j.pvr.2018.05.002. PMID: 29807210.